ATR and cancer: Key exclusion criteria included treatment with chemotherapy; small molecule or biologic anti-cancer therapy within 14 d before first dose of the study drug; or prior therapy with an ATR or DNA-dependent protein kinase (DNA-PK) inhibitor.